by TrN2016_SandWich | Apr 12, 2016 |
Andrew Charles Andrew has more than 25 years experience in the pharmaceutical industry across all phases of drug discovery from early target identification and validation to late PhIIb. During his career in AstraZeneca, Andrew has worked as a bioscientist in several...
by TrN2016_SandWich | Apr 12, 2016 |
Charles Phillips Charles has extensive experience in medical leadership of face to face meetings with regulators in the US, UK, Canada and Australia. Providing the clinical overview for registration filings of a biologic product, Type II variations on existing...
by TrN2016_SandWich | Apr 12, 2016 |
Elna van der Ryst Dr van der Ryst is a physician with extensive postgraduate training in virology and infectious diseases, including a PhD in molecular virology from the University of the Free State in Bloemfontein, South Africa. In addition she completed a...
by TrN2016_SandWich | Apr 12, 2016 |
Gilles Hanton Gilles Hanton graduated as Doctor in Veterinary Medicine in 1976 and as Diplomate of the American Board of Toxicology in 1990. After academic activities, he started his career in the Pharmaceutical Industry in 1984 and worked first for 2.5 years as...
by TrN2016_SandWich | Apr 12, 2016 |
Elizabeth Peers Elizabeth Peers has worked in clinical development since 1983, starting at Astra, initially in respiratory and cardiovascular phase 3/4 development before moving to gastrointestinal (omeprazole); she followed this with 17 years working in...
